tbuckley/cabot-search huggingface dataset:
Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series
Authors: Carlo A. Bravi, Nicola Fossati, Giorgio Gandaglia, Nazareno Suardi, Elio Mazzone, Daniele Robesti, Daniar Osmonov, Klaus-Peter Juenemann, Luca Boeri, R. Jeffrey Karnes, Alexander Kretschmer, Alexander Buchner, Christian Stief, Andreas Hiester, Alessandro Nini, Peter Albers, Gaëtan Devos, Steven Joniau, Hendrik Van Poppel, Shahrokh F. Shariat, Axel Heidenreich, David Pfister, Derya Tilki, Markus Graefen, Inderbir S. Gill, Alexander Mottrie, Pierre I. Karakiewicz, Francesco Montorsi, Alberto Briganti
Journal: European Urology (2020)
Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults
Authors: Robert Chiesa, Junfeng Wang, Henric-Jan Blok, Sheree Hazelaar, Benedicte Neven, Despina Moshous, Ansgar Schulz, Manfred Hoenig, Fabian Hauck, Amal Al Seraihy, Jolanta Gozdzik, Per Ljungman, Caroline A. Lindemans, Juliana F. Fernandes, Krzysztof Kalwak, Brigitte Strahm, Urs Schanz, Petr Sedlacek, Karl-Walter Sykora, Serap Aksoylar, Franco Locatelli, Polina Stepensky, Robert Wynn, Su Han Lum, Marco Zecca, Fulvio Porta, Mervi Taskinen, Brenda Gibson, Susanne Matthes, Musa Karakukcu, Mathias Hauri-Hohl, Paul Veys, Andrew R. Gennery, Giovanna Lucchini, Matthias Felber, Michael H. Albert, Dmitry Balashov, Arjan Lankester, Tayfun Güngör, Mary A. Slatter
Journal: Blood (2020)
Giant T Wave Inversion and Dyspnea in the Time of Coronavirus Pandemic
Authors: Alejandro Cruz-Utrilla, Teresa Segura De la Cal, Pilar Escribano-Subias
Journal: Circulation (2020)

ECG CHALLENGEA 21-year-old man with a previous history of stage I sarcoidosis with mild lung impairment was admitted to the emergency department for 2-week exertional dyspnea and bilateral leg edema.He had no fever or cough and decided not to consult previously because of coronavirus disease 2019 (COVID-19) lockdown.At physical examination, there were bilateral rales.Nt-proBNP (Nterminal pro-B-type natriuretic peptide) was 7737 pg/mL and hs-T-Troponin (high-sensitivity troponin T) was 24 ng/L (normal, <14 ng/L), with the rest of his blood test parameters unremarkable.Initial ECG can be observed in Figure 1.A transthoracic echocardiography was performed, showing a severely dilated right ventricle (RV) with systolic dysfunction, systolic interventricular septum deviation, and an eccentricity index of 1.4; these findings are suggestive of pressure overload (Figure 2).The estimated systolic pressure of the pulmonary artery was 66 mm Hg.A computed tomography angiography was performed, revealing bilateral pulmonary infiltrates and ground-glass opacities, bilateral hilar lymphadenopathies that related to the previous diagnosis of sarcoidosis, and main pulmonary artery and RV enlargement in the context of the presumed pulmonary hypertension (PH; Figure 3).Pulmonary embolism (PE) was excluded.Considering the high prevalence of COVID-19 infection in the area of Madrid (Spain) at the time of the patient's admission, a nasopharyngeal swab was obtained and a real-time polymerase chain reaction test for this virus was carried out, with negative results.The patient was hospitalized for further study.What is the most likely diagnosis?What does this ECG pattern show?Please turn the page to read the diagnosis.
Taurine Metabolism Aggravates the Progression of Lupus by Promoting the Function of Plasmacytoid Dendritic Cells
Authors: Jun Li, Huihua Ding, Yao Meng, Guanhua Li, Qiong Fu, Qiang Guo, Zhihua Yin, Zhizhong Ye, Haibo Zhou, Nan Shen
Journal: Arthritis & Rheumatology (2020)

Type I interferons (IFNs) are critical in the development of systemic lupus erythematosus (SLE). Metabolic abnormalities cause dysregulation of multiple immune cells, but the metabolic regulation of type I IFN production is not well clarified in SLE. We undertook this study to define amino acid metabolism features in SLE and to explore the function of disease-relevant metabolites in the control of plasmacytoid dendritic cell (pDC)-mediated type I IFN production and the progression of SLE.Metabolomic profiling of the serum from SLE patients and healthy controls was performed by mass spectrometry. The effects of SLE-related metabolites on type I IFN production were explored in human and mouse pDCs. The reactive oxygen species (ROS) levels of pDCs from wild-type and Ncf1-/- mice were measured by flow cytometry. Mechanisms were investigated by RNA sequencing and immunoblotting. In vivo effects of SLE-relevant metabolites were systemically analyzed in B6.Cg-Sle1NZM2410/Aeg Yaa/DcrJ mice.Taurine was higher in the serum from SLE patients compared to healthy controls (P < 0.001) and rheumatoid arthritis patients (P < 0.001). Taurine content was positively correlated with disease activity and the expression of IFN signature genes. The addition of taurine facilitated IFN regulatory factor 7 phosphorylation and enhanced type I IFN production by reducing the ROS levels in pDCs in a neutrophil cytosolic factor 1-dependent manner. Taurine supplementation promoted expression of type I IFN-induced genes, activated lymphocytes, and increased autoantibodies and proteinuria, leading to more serious nephritis.Taurine metabolism is involved in the development of SLE by enhancing pDC-mediated type I IFN production. Targeted inhibition of taurine or implementation of a taurine-restricted diet has therapeutic potential in SLE.
Alteration of taste or smell as a predictor of COVID-19
Authors: Jyh-Ming Liou, Mei-Jyh Chen, Tzu-Chan Hong, Ming-Shiang Wu
Journal: Gut (2020)

We read the studies by Jin et al 1 and Lin et al 2 regarding the GI manifestations in COVID-19 with great interest. Recently, alteration in taste (dysgeusia, hypogeusia, ageusia) or smell (dysosmia, hyposmia, anosmia) has been increasingly reported in Western patients with COVID-19.3–10 However, these symptoms were not reported from these two studies from China.1 2 Therefore, we conducted a systematic review and meta-analysis to assess the prevalence of taste or smell alteration in patients with COVID-19 and to calculate the accuracy of these symptoms in the prediction of COVID-19. We searched articles in the PubMed database from 1 January 2020 through 10 May 2020 using the keywords “COVID-19” and “taste” or “smell” without any limitations in the search fields (registration number: CRD42020187912).

Of the 48 articles identified using the above search strategy, 30 were excluded (9 irrelevant, 9 comments, 5 review articles, 5 case reports, 2 series of cases with taste/smell alteration) and 18 were eligible for meta-analysis (study methods and references can be found in the online supplementary materials).1–5 …
Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E – The HepNet SofE pilot study
Authors: Markus Cornberg, Sven Pischke, Tobias Müller, Patrick Behrendt, Felix Piecha, Julia Benckert, Daniel Todt, Eike Steinmann, Armin Papkalla, Maria von Karpowitz, Armin Koch, Ansgar Lohse, Svenja Hardtke, Michael P. Manns, Heiner Wedemeyer
Journal: Journal of Hepatology (2020)
COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
Authors: Jixin Zhong, Guifen Shen, Huiqin Yang, Anbin Huang, Xiaoqi Chen, Li Dong, Bin Wu, Anbin Zhang, Linchong Su, Xiaoqiang Hou, Shulin Song, Huiling Li, Wenyu Zhou, Tao Zhou, Qin Huang, Aichun Chu, Zachary Braunstein, Xiaoquan Rao, Cong Ye, Lingli Dong
Journal: The Lancet Rheumatology (2020)

In the ongoing COVID-19 pandemic, the susceptibility of patients with rheumatic diseases to COVID-19 remains unclear. We aimed to investigate susceptibility to COVID-19 in patients with autoimmune rheumatic diseases during the ongoing COVID-19 pandemic.We did a multicentre retrospective study of patients with autoimmune rheumatic diseases in Hubei province, the epicentre of the COVID-19 outbreak in China. Patients with rheumatic diseases were contacted through an automated telephone-based survey to investigate their susceptibility to COVID-19. Data about COVID-19 exposure or diagnosis were collected. Families with a documented history of COVID-19 exposure, as defined by having at least one family member diagnosed with COVID-19, were followed up by medical professionals to obtain detailed information, including sex, age, smoking history, past medical history, use of medications, and information related to COVID-19.Between March 20 and March 30, 2020, 6228 patients with autoimmune rheumatic diseases were included in the study. The overall rate of COVID-19 in patients with an autoimmune rheumatic disease in our study population was 0·43% (27 of 6228 patients). We identified 42 families in which COVID-19 was diagnosed between Dec 20, 2019, and March 20, 2020, in either patients with a rheumatic disease or in a family member residing at the same physical address during the outbreak. Within these 42 families, COVID-19 was diagnosed in 27 (63%) of 43 patients with a rheumatic disease and in 28 (34%) of 83 of their family members with no rheumatic disease (adjusted odds ratio [OR] 2·68 [95% CI 1·14-6·27]; p=0·023). Patients with rheumatic disease who were taking hydroxychloroquine had a lower risk of COVID-19 infection than patients taking other disease-modifying anti-rheumatic drugs (OR 0·09 [95% CI 0·01-0·94]; p=0·044). Additionally, the risk of COVID-19 was increased with age (adjusted OR 1·04 [95%CI 1·01-1·06]; p=0·0081).Patients with autoimmune rheumatic disease might be more susceptible to COVID-19 infection than the general population.National Natural Science Foundation of China and the Tongji Hospital Clinical Research Flagship Program.
Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis
Authors: Angela Lopez-Sainz, Fernando Dominguez, Luis Rocha Lopes, Juan Pablo Ochoa, Roberto Barriales-Villa, Vicente Climent, Marijke Linschoten, Coloma Tiron, Chiara Chiriatti, Nuno Marques, Torsten B. Rasmussen, María Ángeles Espinosa, Roy Beinart, Giovanni Quarta, Sergi Cesar, Ella Field, Jose M. Garcia-Pinilla, Zofia Bilinska, Alison R. Muir, Angharad M. Roberts, Enrique Santas, Esther Zorio, Maria Luisa Peña-Peña, Marina Navarro, Adrian Fernandez, Julian Palomino-Doza, Olga Azevedo, Massimiliano Lorenzini, Maria I. García-Álvarez, Dina Bento, Morten K. Jensen, Irene Méndez, Laura Pezzoli, Georgia Sarquella-Brugada, Oscar Campuzano, Esther Gonzalez-Lopez, Jens Mogensen, Juan Pablo Kaski, Michael Arad, Ramon Brugada, Folkert W. Asselbergs, Lorenzo Monserrat, Iacopo Olivotto, Perry M. Elliott, Pablo Garcia-Pavia, Torsten B. Rasmussen, Morten K. Jensen, Roberto Barriales, Jose María Larrañaga-Moreira, Diego Alonso-García, Ivonne Johana Cárdenas-Reyes, Marcos Cicerchia, German García-Ferro, Soledad García-Hernández, Lorenzo Monserrat, María Nöel-Bröger, Juan Pablo Ochoa, Martin Ortiz, Pedro Azevedo, Dina Bento, João Bispo, Teresa Mota, Raquel Fernandes, Hugo Costa, Nuno Marques, Vicente Climent, Maria I. García-Álvarez, Sergi Cesar, Georgia Sarquella-Brugada, Alison R. Muir, Laura Pezzoli, Giovanni Quarta, Adrian Fernandez, Ella Field, Juan Pablo Kaski, Olga Azevedo, Enrique Santas, Chiara Chiriatti, Iacopo Olivotto, Ramon Brugada, Oscar Campuzano, Coloma Tiron, Olga Azevedo, Julian Palomino Doza, Rafael Salguero-Bodes, Maria Valverde-Gomez, Maria Angeles Espinosa, Irene Mendez, Marta Cobo-Marcos, Fernando Domínguez, Luis Escobar, Pablo Garcia-Pavia, Esther González-López, Ángela López-Sainz, Javier Segovia-Cubero, Silvia Vilches, Jose Manuel Garcia-Pinilla, Ainhoa Robles-Mezcua, Miguel López-Garrido, Luis Morcillo Hidalgo, Victoria Doncel Abad, Marina Navarro, Maria Sabater-Molina, Juan Ramón Gimeno-Blanes, Esther Zorio, Maria Luisa Peña-Peña, Jens Mogensen, Paul J. Barton, Stuart A. Cook, Angharad M. Roberts, James S. Ware, Michael Arad, Roy Beinart, Perry M. Elliott, Luis Rocha Lopes, Massimiliano Lorenzini, Petros Syrris, Grażyna Truszkowska, Ewa Michalak, Rafal Ploski, Zofia Bilińska, Folkert Asselbergs, Annette F. Baas, Dennis Dooijes, Marijke Linschoten
Journal: Journal of the American College of Cardiology (2020)
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Authors: Thilo Gambichler, Judith Reuther, Christina H Scheel, Jürgen Christian Becker
Journal: Journal for ImmunoTherapy of Cancer (2020)

The present review summarizes up-to-date evidence addressing the frequently discussed clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer patients with viral infections, including AIDS, hepatitis B and C, progressive multifocal leukoencephalopathy, influenza, and COVID-19. In detail, we provide available information on (1) safety regarding the risk of new infections, (2) effects on the outcome of pre-existing infections, (3) whether immunosuppressive drugs used to treat ICI-related adverse events affect the risk of infection or virulence of pre-existing infections, (4) whether the use of vaccines in ICI-treated patients is considered safe, and (5) whether there are beneficial effects of ICIs that even qualify them as a therapeutic approach for these viral infections.
Partha Kar: To tackle racism, the NHS needs policies with teeth
Authors: Partha Kar
Journal: BMJ (2020)

I had to read through the email a few times to digest what a consultant had written to me. “Conflating covid with institutional racism amongst your friends and colleagues is utterly shameful,” it said. “Nobody knows the genetics of covid, but you see fit to suggest that its predilection for BAME [black and minority ethnic people] is down to racism. Your views nauseate me—there is no room for them in today’s NHS.”

The email was in response to my column in May for The BMJ ,1 in which I discussed whether racism was a factor in the increased mortality rate from covid-19 among people from ethnic minority backgrounds. Subsequently, further investigations and a report from Public Health England2 have established that racism and discrimination may have contributed to the increased risk of death from covid-19 among ethnic minority groups. Yet, for the consultant who sent …
Stress Ulcer Prophylaxis for ICU Patients—Reply
Authors: Paul J. Young
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COVID‐19 and asthma, the good or the bad?
Authors: Jiu‐Yao Wang, Ruby Pawankar, Hui‐Ju Tsai, Lawrence Shih‐Hsin Wu, Wen‐Shuo Kuo
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys
Authors: Yuji Nagai, Naohisa Miyakawa, Hiroyuki Takuwa, Yukiko Hori, Kei Oyama, Bin Ji, Manami Takahashi, Xi-Ping Huang, Samuel T. Slocum, Jeffrey F. DiBerto, Yan Xiong, Takuya Urushihata, Toshiyuki Hirabayashi, Atsushi Fujimoto, Koki Mimura, Justin G. English, Jing Liu, Ken-ichi Inoue, Katsushi Kumata, Chie Seki, Maiko Ono, Masafumi Shimojo, Ming-Rong Zhang, Yutaka Tomita, Jin Nakahara, Tetsuya Suhara, Masahiko Takada, Makoto Higuchi, Jian Jin, Bryan L. Roth, Takafumi Minamimoto
Journal: Nature Neuroscience (2020)
Severe Hypoglycemia and Risk of Falls in Type 2 Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
Authors: Alexandra K. Lee, Stephen P. Juraschek, B. Gwen Windham, Clare J. Lee, A. Richey Sharrett, Josef Coresh, Elizabeth Selvin
Journal: Diabetes Care (2020)

OBJECTIVE Hypoglycemia has been postulated to contribute to falls risk in older adults with type 2 diabetes. However, few studies have prospectively examined the association between severe hypoglycemia and falls, both important causes of morbidity and mortality. RESEARCH DESIGN AND METHODS We conducted a prospective cohort analysis of participants from the Atherosclerosis Risk in Communities (ARIC) study with diagnosed diabetes at visit 4 (1996–1998). Episodes of severe hypoglycemia requiring medical treatment were identified using ICD-9 codes from hospitalizations, emergency department visits, and ambulance calls; total falls were identified from medical claims using E-codes from 1996 to 2013. Secondary analyses examined hospitalized falls and falls with fracture. We calculated incidence rates and used Cox regression models to evaluate the independent association of severe hypoglycemia with falls occurring after visit 4 through 2013. RESULTS Among 1,162 participants with diabetes, 149 ever had a severe hypoglycemic event before baseline or during the median of 13.1 years of follow-up. The crude incidence rate of falls among persons without severe hypoglycemia was 2.17 per 100 person-years (PY) (95% CI 1.93–2.44) compared with 8.81 per 100 PY (6.73–11.53) with severe hypoglycemia. After adjustment, severe hypoglycemia was associated with a more than twofold higher risk of falls (hazard ratio 2.23, 95% CI 1.61–3.07). Associations were consistent in subgroups defined by age, sex, race, BMI, duration of diabetes, or functional difficulty. CONCLUSIONS Severe hypoglycemia was associated with a substantially higher risk of falls in this community-based population of adults with diabetes. Fall risk should be considered when individualizing glycemic treatment in older adults. Assessing hypoglycemia history and future hypoglycemia risk could also improve multifactorial fall prevention interventions for older adults with diabetes.
Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the <scp>TECOS</scp> randomized clinical trial
Authors: Finlay A. McAlister, Yinggan Zheng, Cynthia M. Westerhout, John B. Buse, Eberhard Standl, Darren K. McGuire, Frans Van de Werf, Jennifer B. Green, Paul W. Armstrong, Rury R. Holman
Journal: European Journal of Heart Failure (2020)
Abstract 13638: Direct Estimation of Diastolic Function From 2-Dimensional Echocardiography Videos Using Convolutional Neural Networks
Authors: Shinichi Goto, Calum A Macrae, Rahul C Deo
Journal: Circulation (2019)

Introduction: Initial applications of machine learning to echocardiography have focused on replicating human tasks such as detecting views, localizing ventricular boundaries, and recognizing abnorm...
B-cell maturation antigen expression across hematologic cancers: a systematic literature review
Authors: Ahmet Dogan, David Siegel, Nguyet Tran, Alan Fu, Jessica Fowler, Rajesh Belani, Ola Landgren
Journal: Blood Cancer Journal (2020)

B-cell maturation antigen (BCMA) plays a critical role in regulating B-cell proliferation and survival. There is evidence for BCMA expression in various hematologic malignancies, suggesting that BCMA may play an important role as a biomarker or therapeutic target in these diseases. Given advances in understanding the role of BCMA in B-cell development and the promise of BCMA as a therapeutic target, a systematic review is needed to rigorously assess the evidence for BCMA expression and identify areas of consensus and future research. The objective of this review was to summarize the evidence on BCMA protein and mRNA expression across hematologic malignancies. Using a PubMed database search up to 28 August 2019, a systematic literature review of publications reporting BCMA expression in patients with hematologic malignancies was conducted. Data from published congress abstracts presented at the American Society of Clinical Oncology and the American Society of Hematology were also searched. Studies that assessed BCMA expression (protein or mRNA) in patients of any age with hematologic malignancies were included. A total of 21 studies met inclusion criteria and were included in the review. BCMA was expressed in several hematologic malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia, acute B-lymphoblastic leukemia, non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma. BCMA was expressed at uniformly high levels across all 13 MM studies and at low to moderate levels in acute myeloid leukemia and acute lymphoblastic leukemia. These results suggest that BCMA is a relevant target in MM as well as in a subset of B-cell leukemia. BCMA expression in Hodgkin lymphoma and NHL varied across studies, and further research is needed to determine the utility of BCMA as an antibody target and biomarker in these diseases. Differences in sample type, timing of sample collection, and laboratory technique used may have affected the reporting of BCMA levels.
An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients
Authors: Joseph L. Mann, Caitlin L. Maikawa, Anton A. A. Smith, Abigail K. Grosskopf, Sam W. Baker, Gillie A. Roth, Catherine M. Meis, Emily C. Gale, Celine S. Liong, Santiago Correa, Doreen Chan, Lyndsay M. Stapleton, Anthony C. Yu, Ben Muir, Shaun Howard, Almar Postma, Eric A. Appel
Journal: Science Translational Medicine (2020)

Insulin has been used to treat diabetes for almost 100 years; yet, current rapid-acting insulin formulations do not have sufficiently fast pharmacokinetics to maintain tight glycemic control at mealtimes. Dissociation of the insulin hexamer, the primary association state of insulin in rapid-acting formulations, is the rate-limiting step that leads to delayed onset and extended duration of action. A formulation of insulin monomers would more closely mimic endogenous postprandial insulin secretion, but monomeric insulin is unstable in solution using present formulation strategies and rapidly aggregates into amyloid fibrils. Here, we implement high-throughput-controlled radical polymerization techniques to generate a large library of acrylamide carrier/dopant copolymer (AC/DC) excipients designed to reduce insulin aggregation. Our top-performing AC/DC excipient candidate enabled the development of an ultrafast-absorbing insulin lispro (UFAL) formulation, which remains stable under stressed aging conditions for 25 ± 1 hours compared to 5 ± 2 hours for commercial fast-acting insulin lispro formulations (Humalog). In a porcine model of insulin-deficient diabetes, UFAL exhibited peak action at 9 ± 4 min, whereas commercial Humalog exhibited peak action at 25 ± 10 min. These ultrafast kinetics make UFAL a promising candidate for improving glucose control and reducing burden for patients with diabetes.
Magnetically-driven implantable pump for on-demand bolus infusion of short-acting glucagon-like peptide-1 receptor agonist
Authors: Seung Ho Lee, Se Hee Min, Yong Chan Cho, Jae Hoon Han, Mi Na Kim, Cho Rim Kim, Chang Ho Ahn, Byung Hwi Kim, Cheol Lee, Young Min Cho, Young Bin Choy
Journal: Journal of Controlled Release (2020)